Top Page
Elixinol Wellness
(Sydney:EXL)
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Elixinol Wellness Business Overview & Revenue Model
Elixinol Wellness Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.85M | 14.96M | 8.27M | 7.05M | 9.34M | 15.01M |
| Gross Profit | 5.59M | 5.36M | -1.80M | -3.27M | -6.25M | -9.58M |
| EBITDA | -5.00M | -4.01M | -6.81M | -9.28M | -15.51M | -95.94M |
| Net Income | -2.06M | -1.72M | -7.51M | -10.57M | -17.02M | -104.51M |
Balance Sheet | ||||||
| Total Assets | 16.58M | 18.45M | 11.71M | 13.48M | 25.33M | 42.47M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 1.08M | 708.00K | 2.86M | 12.65M | 27.74M |
| Total Debt | 3.10M | 1.94M | 1.26M | 1.83M | 2.71M | 2.74M |
| Total Liabilities | 9.61M | 8.42M | 5.25M | 4.33M | 6.25M | 6.82M |
| Stockholders Equity | 6.96M | 10.03M | 6.46M | 9.16M | 19.08M | 35.65M |
Cash Flow | ||||||
| Free Cash Flow | -2.73M | -3.53M | -2.77M | -8.16M | -14.36M | -22.95M |
| Operating Cash Flow | -2.71M | -3.47M | -2.76M | -8.15M | -14.07M | -22.62M |
| Investing Cash Flow | -516.00K | -66.00K | -1.04M | -869.00K | 172.00K | 2.55M |
| Financing Cash Flow | 2.76M | 3.92M | 1.61M | -757.00K | -1.16M | 27.55M |
Elixinol Wellness Technical Analysis
Elixinol Wellness Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$4.76M | -1.20 | -26.84% | ― | 36.60% | 85.28% | |
46 Neutral | AU$11.75M | -1.79 | -469.43% | ― | -1.25% | -188.33% | |
39 Underperform | AU$17.47M | -0.26 | -401.36% | ― | -26.49% | 61.72% |
Elixinol Wellness Corporate Events
Elixinol Wellness Limited has disclosed a change in the relevant interests of director Gavin Evans, in line with ASX listing rule 3.19A.2 reporting requirements. The director, via a superannuation fund account, acquired 397,010 fully paid ordinary shares in on‑market trades on 19 and 30 December 2025 for a total consideration of $3,820.85, increasing his indirect holding from 7,407,407 to 7,804,417 shares, while his existing 50,000,000 unlisted options remain unchanged. The transactions, which did not occur during a closed trading period, modestly increase Evans’ equity exposure to the company, incrementally aligning his interests with those of other shareholders and signaling continued personal investment in Elixinol Wellness.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has announced a change of auditor following the Australian corporate regulator’s consent to the resignation of BDO Audit, which stepped down effective 18 December 2025 without identifying any reportable matters linked to its departure. The board has appointed RSM Australia as the company’s new auditor, with the move to be put to shareholders for ratification at the next annual general meeting, signalling a routine governance transition rather than a response to financial or compliance concerns.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has revised the acquisition terms for its subsidiary, The Healthy Chef, following the withdrawal of a major US distribution partner, resulting in reduced liabilities and enhanced liquidity by A$1 million. With a focus on the Australian market, supported by strong growth performance in November, Elixinol is aligning investments toward higher-margin opportunities and positioning itself for long-term sustainable growth and improved shareholder value.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has released a report detailing the top holders of its listed options, which are priced at $0.02 and have a two-year expiration from the issue date. The report highlights that 10 Bolivianos Pty Ltd holds the largest share at 15.54%, followed by another significant holding of 13.54% by the same entity. This information provides insights into the company’s shareholder structure and potential influence on its strategic decisions.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has announced a new application for the quotation of securities on the ASX, with a total of 218,796,310 options expiring on October 23, 2027, set to be issued on November 25, 2025. This move is likely to impact the company’s market presence and could influence investor sentiment as it expands its financial instruments.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited has announced the appointment of Gavin Evans as a director, effective December 2, 2025. Evans holds 50,000,000 unlisted options and 7,407,407 fully paid ordinary shares, indicating a significant stake in the company. This appointment may influence the company’s strategic direction and could impact its market positioning, potentially affecting stakeholders’ interests.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness has announced the resignation of David Fenlon as Chair of the Board, with Gavin Evans stepping in as the new Independent Non-Executive Chair. Evans, who has a strong background in building profitable wellness businesses, has been a strategic adviser to Elixinol and is expected to drive the company’s transformation agenda towards profitability. His leadership is anticipated to enhance operational discipline and growth, benefiting stakeholders and supporting the company’s strategic goals.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
Elixinol Wellness Limited announced the cessation of 190,973 securities due to the expiry of options without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.
Elixinol Wellness Limited has announced the quotation of 136,996,310 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of a previously announced transaction, potentially impacting the company’s market presence and offering stakeholders an opportunity to engage with its securities.
Elixinol Wellness Ltd held a General Meeting where shareholders approved several resolutions, including the ratification of prior issue of Tranche 1 Placement Shares and the approval to issue Tranche 2 Placement Shares. These approvals are expected to support the company’s capital structure and facilitate further growth opportunities, enhancing its market position and potentially benefiting stakeholders.
Elixinol Wellness Ltd has announced a reminder for its shareholders about an upcoming extraordinary general meeting scheduled for 10 November 2025. The meeting, initially set for 31 October 2025, has been rescheduled, and shareholders have been provided with an amended Notice of Meeting, Access Letter, and Proxy Form. Proxy voting will close on 8 November 2025, but shareholders can still vote by attending the meeting directly. This meeting is crucial for stakeholders as it provides an opportunity to engage with the company’s strategic direction and decisions.
Elixinol Wellness reported a Q3 revenue of $3.8 million, maintaining its previous year’s performance due to strategic portfolio rationalization. The company achieved a 300 basis point increase in gross margin, driven by e-commerce and core brands, and is implementing cost-reduction measures to enhance operational efficiency. A capital raise of $2.5 million is supporting growth and margin initiatives, with Hemp Foods Australia experiencing its strongest quarter and The Healthy Chef anticipating a rebound in Q4.
Elixinol Wellness Limited has issued a prospectus for the offer of new options to select investors, including up to 1 new option for every new share issued to invited placement investors and 35,000,000 new options to the lead manager for capital raising and advisory services. The offers are not open to the general public, and applications can only be made by invited investors. This move is part of Elixinol’s strategy to raise capital and enhance its market positioning, although the investment is considered speculative and involves risks.
Elixinol Wellness Ltd has postponed its Extraordinary General Meeting originally scheduled for 31 October 2025 to 11 November 2025 due to an administrative error by the share registrar, which failed to notify certain shareholders within the statutory timeframes. The company is committed to ensuring all shareholders have a fair opportunity to participate and vote, and will issue a new Notice of Meeting and related documents. This postponement underscores Elixinol’s dedication to transparency and shareholder engagement, despite the inconvenience caused.
Elixinol Wellness Limited announced the cancellation of a previous securities issuance announcement due to the expiration of the offer period associated with a cleansing prospectus. This decision reflects the company’s adherence to regulatory requirements and impacts its operational plans regarding the proposed non-pro rata offer of securities.